Precigen (PGEN) AI Stock Analysis

• Market Cap: $490.00M
• Dividend Yield: N/A
• Average Volume (3M): 2.32M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.10
• Revenue Growth: -22.76%
• EPS Growth: -46.69%
• Country: US
• Employees: 143
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.18
• Shares Outstanding: 295,180,050
• 10 Day Avg. Volume: 3,363,570
• 30 Day Avg. Volume: 2,317,191
• PEG Ratio: 0.21
• Price to Book (P/B): -38.88
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -7.29
• Enterprise Value/Market Cap: 1.11
• Enterprise Value/Revenue: 33.10
• Enterprise Value/Gross Profit: -5.99K
• Enterprise Value/Ebitda: -1.00
• 1Y Price Target: $6.00
• Price Target Upside: 275.00% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4

• Rating: 50 Neutral
• Price Target: $1.50 ▼(-6.25%Downside)

Precigen's overall stock score reflects significant financial challenges and speculative valuation, offset slightly by positive corporate events that may improve operational flexibility. Technical analysis indicates neutral to mildly positive trends, contributing to a balanced score.

Positive Factors

Clinical Trial Success

In the pivotal Phase 1/2 trial, PRGN-2012 demonstrated that more than 50% of patients achieved a complete response and more than 85% of patients experienced a decrease in surgical interventions.

Regulatory Progress

The FDA has accepted the BLA for PRGN-2012 as a treatment for recurrent respiratory papillomatosis (RRP) and set a PDUFA date, indicating a smooth approval process.

Strategic Partnerships

The company is working with Eversana, an expert in commercialization of rare disease therapies, for the launch of PRGN-2012.

Negative Factors

Commercial Adoption Challenges

Commercial adoption if approved will take time, with only one site at the NIH experienced in administering the treatment, and critical factors like cold chain storage and cost-related barriers to consider.

Financial Performance

For FY24, Precigen reported total revenue of $3.9M and a net loss of $0.47 per share, compared to the consensus estimated revenue of $4.1M and a net loss of 0.46 per share.

Pricing Concerns

Physicians express concerns about payor access if the treatment is priced in the $250K-$400K range, which could be a potential obstacle.

Precigen Business Overview & Revenue Model

Company Description

Precigen, Inc. is a biotechnology company focused on the development of innovative gene and cell therapies. Operating primarily within the healthcare and life sciences sectors, Precigen aims to advance the next generation of gene and cell therapies to address unmet medical needs in areas such as oncology, autoimmune disorders, and infectious diseases. The company leverages its proprietary UltraCAR-T, ActoBiotics, and AdenoVerse platforms to create targeted and effective treatments.

How the Company Makes Money

Precigen generates revenue through a combination of strategic partnerships, collaborations, and licensing agreements. The company partners with other biotechnology and pharmaceutical companies to co-develop and commercialize its therapeutic candidates, receiving milestone payments and royalties as these products advance through clinical development and reach the market. Additionally, Precigen licenses its proprietary technology platforms to third parties, generating licensing fees and other related revenues. The company's earnings are also supported by government grants and research funding, which contribute to the advancement of its research and development initiatives.

Precigen Financial Statement Overview

Summary

Precigen's financial performance is severely challenged. The income statement shows declining revenues and negative profit margins, with a net profit margin at -3728.79% TTM. The balance sheet reveals negative stockholders' equity and high liabilities, indicating financial instability. Cash flow is negative overall, with some improvement in operating cash flow but heavy reliance on financing.

Income Statement

Precigen's income statement reflects significant challenges with declining revenues and negative profit margins. The gross profit margin is negative at -2.17% TTM, indicating costs exceed sales. The net profit margin is also severely negative at -3728.79% TTM, showing substantial losses. Revenue has decreased drastically over recent periods, with a TTM revenue growth rate of -32.56%. EBIT and EBITDA margins are also negative, highlighting ongoing operational inefficiencies.

Balance Sheet

The balance sheet shows financial instability, with negative stockholders' equity of -$14.06 million TTM, indicating liabilities exceed assets. The debt-to-equity ratio isn't applicable due to negative equity, but the presence of high total liabilities of $142.85 million suggests significant leverage. The equity ratio is negative, further emphasizing the weak financial position. Return on equity is not applicable due to negative equity.

Cash Flow

Cash flow analysis shows continuous negative free cash flow, with a slight improvement in operating cash flow. Free cash flow growth rate is slightly positive at 1.95% TTM, but remains negative overall at -$75.26 million. The operating cash flow to net income ratio is 0.45 TTM, reflecting some operational cash generation despite losses. However, the company is heavily reliant on financing activities for cash inflow.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.92M	6.22M	26.91M	103.87M	103.18M
Gross Profit	-342.00K	106.00K	20.57M	45.49M	47.66M
EBITDA	-123.50M	-89.23M	-66.00M	-84.07M	-70.41M
Net Income	-126.23M	-95.90M	-79.78M	-96.77M	-103.77M
Balance Sheet
Total Assets	145.27M	151.04M	215.98M	359.86M	314.59M
Cash, Cash Equivalents and Short-Term Investments	97.91M	62.85M	55.95M	115.16M	100.12M
Total Debt	5.50M	7.10M	51.42M	194.20M	182.28M
Total Liabilities	106.75M	32.55M	89.72M	252.51M	247.41M
Stockholders Equity	38.51M	118.50M	126.26M	107.35M	67.17M
Cash Flow
Free Cash Flow	-76.76M	-68.47M	-69.97M	-63.02M	-84.55M
Operating Cash Flow	-68.17M	-66.93M	-65.05M	-55.77M	-77.02M
Investing Cash Flow	-20.71M	-3.09M	226.42M	-74.54M	27.78M
Financing Cash Flow	110.58M	29.59M	-155.29M	121.19M	32.70M

Precigen Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.60
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PGEN, the sentiment is Neutral. The current price of 1.6 is below the 20-day moving average (MA) of 1.69, above the 50-day MA of 1.52, and above the 200-day MA of 1.32, indicating a neutral trend. The MACD of 0.05 indicates Positive momentum. The RSI at 47.54 is Neutral, neither overbought nor oversold. The STOCH value of 23.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PGEN.

Precigen Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MGTX	60 Neutral	$682.30M	―	-216.14%	―	203.23%	-80.71%
RLAY	57 Neutral	$649.78M	―	-45.46%	―	-78.26%	15.41%
Sector *	52 Neutral	$7.61B	0.10	-63.03%	2.08%	16.34%	0.32%
PGEN	50 Neutral	$490.00M	―	-278.55%	―	-22.76%	-46.69%
TYRA	41 Neutral	$574.85M	―	-27.04%	―	―	6.72%
MNMD	40 Neutral	$748.73M	―	-37.07%	―	―	26.24%
SANA	33 Underperform	$1.16B	―	-71.44%	―	―	19.94%

Precigen Corporate Events

Precigen Announces Key Approvals at Annual Meeting

At the Annual Meeting of Stockholders on June 26, 2025, Precigen, Inc. announced several key approvals, including an amendment to increase the shares available under its 2023 Omnibus Incentive Plan by 11.5 million. Additionally, stockholders approved increasing the company’s authorized shares of common stock by 300 million and ratified Deloitte & Touche LLP as the independent accounting firm for 2025. These decisions are expected to impact Precigen’s operational flexibility and shareholder value positively.

The most recent analyst rating on (PGEN) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Precigen stock, see the PGEN Stock Forecast page.